Selecting the right system for metabolite identification

Jul 14, 2023 | Blogs, LC, Pharma, SCIEX OS software, ZenoTOF 7600 system | 0 comments

Read Time: 3 minutes

So, you need a new liquid chromatography-mass spectrometry (LC-MS) system for your metabolite identification (metID) studies, and you are not sure which option is right for you. This blog provides an overview of the metID solutions offered by SCIEX, so you can make the best decision for your organization.

This is the first in a series of blogs intended to help you choose a system that meets your pharmaceutical research and development needs. We hope you find their guidance useful.

Let’s start with a simple question: Which of the following would help you sleep well at night?

  • A: knowing your batch of samples will be complete by your deadline
  • B: a clear identification of the site of metabolism for those extra complex samples

We have great news for you: SCIEX has solutions for enabling both A and B. Let’s take a closer look.

Scenario A
Let’s say you are looking for a system that will run larger batches of samples, and your analytes typically fragment well using collision-induced dissociation (CID), allowing confident identification of the site of metabolism without the need for additional confirmatory testing.

For a complex analysis, the requirements are relatively straightforward, and the priorities are probably ease of use and a robust system that does the job day in and day out. For this scenario, SCIEX recommends using the ExionLC 2.0+ system coupled to the X500R QTOF system, SCIEX OS software and maintenance with SCIEX service and support.
The workflow described in the technical note Targeted high-resolution metabolite screening workflows demonstrates the performance you can expect from this solution.

Scenario B
Suppose you have several samples where clear identification of the site of metabolism is not possible using CID. In this case, the use of a secondary analytical technique, such as nuclear magnetic resonance (NMR), is often required to meet regulatory requirements. Since this approach can be both time-consuming and expensive, an LC-MS system with more analytical power is ideal. Potent therapeutics is another common challenge in this type of scenario, which makes method sensitivity a key requirement for detecting low-abundant metabolites.

In these circumstances, SCIEX recommends using the ExionLC 2.0+ system coupled to the ZenoTOF 7600 system, SCIEX OS software and maintenance with SCIEX service and support.

The ZenoTOF 7600 system features the Zeno trap for enhanced sensitivity and electron activated dissociation (EAD) as a complementary fragmentation option. EAD typically fragments the metabolite in different locations, which can provide the additional information required for clear identification of the site of metabolism from a single analytical technique.

The workflow described in the technical note Confident characterization and identification of glucuronide metabolites using diagnostic fragments from electron activated dissociation (EAD) is a useful example of this solution.

Learn more
For more information on the options SCIEX offers for metID, please speak to your account manager or visit our web page on comprehensive metID.

PFAS testing: 2024 in review and what to expect for 2025

For as long as PFAS persist in the environment, there is no doubt they will persist in our conversations as environmental scientists. Globally, PFAS contamination has been detected in water supplies, soil and even in the blood of people and wildlife. Different countries are at various stages of addressing PFAS contamination and many governments have set regulatory limits and are working on assessing the extent of contamination, cleaning up affected sites and researching safer alternatives.

Inside the box: Acoustic ejection mass spectrometry for drug discovery

On average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use. Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.

Unveiling the power of ZT Scan DIA: Insights from Ludwig Sinn’s presentation at World HUPO Congress 2024

In a recent presentation at the World HUPO Congress 2024, Ludwig Sinn from the Ralser lab shared exciting advancements in proteomics research, focusing on the innovative ZT Scan DIA acquisition modes developed in collaboration with SCIEX. Let us explore the key highlights and benefits of this innovative technology.

Posted by

Kirsten Craven is the Senior Global Marketing Manager for Pharma global strategic marketing at SCIEX. In this role, she manages strategic marketing for the pharmaceutical industry. Kirsten spent the first part of her career working in laboratories across multiple industries before moving into product management, and most recently pharma marketing.

Tags


0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial